Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Short-Term Debt issuances (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Short-Term Debt issuances for 8 consecutive years, with $25.8 million as the latest value for Q3 2025.

  • Quarterly Short-Term Debt issuances fell 3.7% to $25.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $103.9 million through Sep 2025, down 4.85% year-over-year, with the annual reading at $112.6 million for FY2024, 44.01% up from the prior year.
  • Short-Term Debt issuances for Q3 2025 was $25.8 million at Xtant Medical Holdings, down from $26.7 million in the prior quarter.
  • The five-year high for Short-Term Debt issuances was $30.4 million in Q1 2024, with the low at $10.1 million in Q3 2022.
  • Average Short-Term Debt issuances over 5 years is $20.6 million, with a median of $19.8 million recorded in 2023.
  • The sharpest move saw Short-Term Debt issuances dropped 24.73% in 2022, then skyrocketed 88.76% in 2023.
  • Over 5 years, Short-Term Debt issuances stood at $13.6 million in 2021, then grew by 29.09% to $17.5 million in 2022, then skyrocketed by 30.34% to $22.9 million in 2023, then rose by 15.09% to $26.3 million in 2024, then fell by 2.14% to $25.8 million in 2025.
  • According to Business Quant data, Short-Term Debt issuances over the past three periods came in at $25.8 million, $26.7 million, and $25.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.